Niacin Cures Systemic NAD + Deficiency and Improves Muscle Performance in Adult-Onset Mitochondrial Myopathy

Patients with mitochondrial myopathy (which is associated with NAD+ deficiency) received ~1g niacin daily for 4 months. This resulting in increasing blood NAD+ levels in all patients, up to 8x, improved muscle strength, improved respiratory chain activity and reduced fatty liver.

Overview

This 2020 study (Pirinen et al., Cell Metabolism) is among the most important clinical demonstrations of niacin’s role as a NAD+ precursor. It enrolled patients with adult-onset mitochondrial myopathy — a condition characterized by systemic NAD+ deficiency caused by mitochondrial DNA mutations — and treated them with niacin (nicotinic acid) at approximately 1 gram per day for four months.

The results are some of the most striking in the niacin literature: NAD+ levels in blood and muscle rose dramatically in all patients, with some showing up to an 8-fold increase in muscle NAD+ concentration. Alongside the biochemical changes, patients showed measurable improvements in muscle strength and respiratory chain activity, and reduced liver fat accumulation.

Key Findings

NAD+ increased up to 8-fold in blood and muscle. This magnitude of NAD+ restoration from oral niacin is exceptional. NAD+ is central to mitochondrial energy production (as a cofactor in the electron transport chain) and to sirtuin and PARP enzyme activity (which govern DNA repair, gene expression, and cellular stress responses). In mitochondrial myopathy patients, where NAD+ is chronically depleted, this restoration is functionally significant.

Muscle strength improved. Patients showed measurable gains in muscle performance metrics over the four-month period. Given that mitochondrial myopathy is a progressive condition, any functional improvement — rather than just biochemical marker change — represents a clinically meaningful outcome.

Respiratory chain activity recovered. The complexes of the mitochondrial electron transport chain (particularly Complex I) showed improved activity. This is the direct downstream consequence of restored NAD+ availability: more NAD+ means more electron transfer through Complex I, more ATP synthesis, and better mitochondrial function.

Fatty liver was reduced. Liver fat accumulation is a secondary consequence of mitochondrial dysfunction and NAD+ depletion. Its reduction with niacin treatment is consistent with the well-documented role of NAD+ in hepatic lipid metabolism and niacin’s direct effects on the liver.

Why Niacin Works Here: The NAD+ Precursor Pathway

Niacin (nicotinic acid) is one of three main NAD+ precursors, alongside nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). What distinguishes nicotinic acid from the others is the pathway it uses:

• Nicotinic acid enters the Preiss-Handler pathway: nicotinic acid → NaMN → NaAD → NAD+. This pathway is distinct from the NR/NMN salvage pathway.
• In disease states where specific salvage enzymes are depleted or dysfunctional, the Preiss-Handler route may be more effective at restoring NAD+.
• Nicotinic acid also engages the de novo synthesis pathway more directly in some tissues than NR or NMN.

In this study, the dramatic NAD+ restoration from nicotinic acid suggests that in mitochondrial myopathy, the Preiss-Handler pathway is intact and capable of processing high niacin doses into NAD+ even when mitochondrial function is compromised.

Niacin vs. Other NAD+ Precursors

This study is frequently cited in debates about which NAD+ precursor is most effective clinically. While NR and NMN have been studied primarily for aging-related NAD+ decline, niacin’s Preiss-Handler pathway provides a distinct and potentially complementary route.

The 8-fold NAD+ increase from nicotinic acid in this disease population substantially exceeds most reported results from NR or NMN in typical aging populations (which tend to show 40–60% increases in blood NAD+). Whether this gap is disease-specific, dose-specific, or a genuine pathway advantage remains an open research question. This study does not directly compare nicotinic acid to NR or NMN in the same patients.

Clinical Context

Mitochondrial myopathy is a rare disease and the trial was small. The dramatic results should not be extrapolated directly to healthy aging populations. However, the study provides clear proof of concept that:

1. Oral niacin (nicotinic acid) meaningfully and dramatically raises systemic NAD+ levels
2. NAD+ deficiency reversal can translate to measurable functional improvement, not just biochemical marker change
3. Nicotinic acid specifically — not niacinamide, NR, or NMN — was the intervention studied and found effective here

For researchers working on niacin, NAD+ metabolism, aging, mitochondrial disease, or muscle function, this Cell Metabolism paper is foundational. It is the most direct human evidence that niacin supplementation is a potent NAD+ repletion strategy, not merely a lipid-modifying drug.